AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline added intrathecally
Description: Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
Study NCT00409448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor-assisted problem solving (CAPS)
Description: In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
Study NCT00409448 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-resource comparison (IRC)
Description: Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
Study NCT00741286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Asprin (100mg) plus placebo
Study NCT00741286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: Aspirin (100mg) plus cilostazol (200mg)
Study NCT02634359 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EarlySense home device
Description: Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
Study NCT02634359 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vaginal ultrasound
Description: Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
Study NCT02634359 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Test
Description: Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline intrathecally
Description: 0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution intravenously
Description: Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ringer's Lactate solution intravenously
Description: Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomidine intrathecally
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmetomidine intrathecally
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmetomidine intrathecally
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
Study NCT04870398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vital Pulp therapy-Partial pulpotomy
Description: Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
Study NCT02313350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis with Discogel
Description: Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
Study NCT02313350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open discectomy
Description: The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
Study NCT02300467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120401
Description: 5 to 45 mg/day PO for 5 consecutive days and 2 days off
Study NCT02063659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets
Study NCT02063659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching telotristat etiprate tablets
Study NCT02063659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching telotristat etiprate tablets
Study NCT01532999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
Study NCT01532999 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Present Centered Group Therapy
Description: The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
Study NCT02454439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CRT implantation
Study NCT02454439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT implantation
Study NCT00803400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
Study NCT00803400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam + Aerobic exercise
Description: The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association).
Study NCT02178254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Description: A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
Study NCT02178254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
Study NCT03065621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
Study NCT04574414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological testing and MRI imaging
Description: Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI.
Study NCT01425359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study NCT01425359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine placebo
Study NCT01425359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine placebo
Study NCT01631747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Group
Description: Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
Study NCT01631747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
Study NCT04452435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21
Study NCT04452435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01984463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
Study NCT01984463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
Study NCT04202224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and Acetaminophen 500 mg
Description: Analgesia.
Study NCT04202224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Placebo.
Study NCT04202224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No drug
Description: Standard surgical procedure without any preoperative medication.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 15 mg Methotrexate is weekly administered to all the patients.
Study NCT05299281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Micropulse transscleral cyclophotocoagulation (MP-TSCPC)
Description: patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively.
Study NCT03107936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smokeSCREEN game
Description: smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
Study NCT04201860 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood gas analyses and haemostasis measures
Description: Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
Study NCT04341389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
Description: Intramuscular injection
Study NCT04341389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT02756689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient cervical ripening
Description: Subjects will undergo cervical ripening in the inpatient setting.
Study NCT02756689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient cervical ripening
Description: Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
Study NCT03402386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet
Study NCT01996982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCS Device
Description: Core Cooling System Device
Study NCT00859768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
Study NCT01574326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
Study NCT01574326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
Study NCT01574326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevelamer carbonate
Description: 0.8 g sachets of powder for oral suspension or 800 mg tablets
Study NCT01574326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: 0.8 g sachets of powder for oral suspension or 800 mg tablets
Study NCT00371423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté™-SR
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT00371423 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS Liberté™-SR
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT04360954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: There is no intervention. This study will test deidentified archived biosamples.
Study NCT04224311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: 0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
Study NCT04052893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded Mckissock surgery
Description: Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
Study NCT04052893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy
Description: The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
Study NCT04334629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Lipid ibuprofen 200 mg
Study NCT01450839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
Study NCT01450839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablets and tape
Study NCT00505531 — intervention group
Intervention type: DRUG
Intervention: Tramadol Extended Release Oral Capsule
Description: Tramadol ER- up to either 200 mg or 300 mg based on randomization
Study NCT00505531 — intervention group
Intervention type: DRUG
Intervention: Benadryl
Description: Placebo group will take up to 25 mg of Benadryl
Study NCT01723852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D at 30 ug/day
Study NCT01723852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D at 10 ug/day
Study NCT00237198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT01680705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Volume Saline Irrigation
Description: High volume saline irrigation (240 ml)
Study NCT01585194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01585194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01585194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01957644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT01957644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg Methotrexate is weekly administered to all the patients.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: At least 1 mg Folic acid is daily administered to all the patients.
Study NCT01336920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV
Study NCT03117101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Study NCT01806948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramosetron
Study NCT01806948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Study NCT02630433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Index cholecystectomy
Description: Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
Study NCT02630433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled cholecystectomy
Description: Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: At least 1 mg Folic acid is daily administered to all the patients.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7.5 mg Prednisolone is daily administered to all the patients.
Study NCT03172325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 7.5 mg Prednisolone is daily administered to all the patients.
Study NCT04694352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jumping Exercises
Description: Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
Study NCT02356744 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound assessment of fetal growth, anomalies , liqour and placenta